

such findings, and may result in the issuance of an exclusion order or a cease and desist order or both directed against the respondent.

Issued: September 4, 2013.
By order of the Commission.

Lisa R. Barton,

Acting Secretary to the Commission.

[FR Doc. 2013-21843 Filed 9-6-13; 8:45 am]

BILLING CODE 7020-02-P

INTERNATIONAL TRADE COMMISSION

[USITC SE-13-022]

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: United States International Trade Commission.

TIME AND DATE: September 12, 2013 at 11:00 a.m.

PLACE: Room 101, 500 E Street SW., Washington, DC 20436, Telephone: (202) 205-2000.

STATUS: Open to the public.

MATTERS TO BE CONSIDERED:

1. Agendas for future meetings: none
2. Minutes
3. Ratification List
4. Vote in Inv. No. 731-TA-919 (Second Review)(Welded Large Diameter Line Pipe from Japan). The Commission is currently scheduled to complete and file its determinations and views of the Commission on or before September 26, 2013.
5. Outstanding action jackets: none
In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting.

By order of the Commission.
Issued: September 5, 2013.

William R. Bishop,

Supervisory Hearings and Information Officer.

[FR Doc. 2013-21994 Filed 9-5-13; 4:15 pm]

BILLING CODE 7020-02-P

DEPARTMENT OF JUSTICE

Notice of Lodging of Proposed Consent Decrees Under the Comprehensive Environmental Response, Compensation, and Liability Act

Notice is hereby given that on September 3, 2013, a proposed Consent Decree in *United States v. Vermont Asbestos Group, Inc.*, Civil Action No. 2:13-cv-00238-wks, between the United States, State of Vermont, and

Vermont Asbestos Group, Inc. was lodged with the United States District Court for the District of Vermont.

In the United States' action brought under Sections 106, 107, and 113(g)(2) of the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, 42 U.S.C. 9606, 9607 and 9613(g)(2) ("CERCLA"), the United States seeks injunctive relief requiring the Vermont Asbestos Group ("Settling Defendant") to perform the operation and maintenance of the erosion control structures constructed by the United States Environmental Protection Agency at the Vermont Asbestos Group Mine Superfund Site in Lowell and Eden, Vermont. The United States also seeks to recover costs incurred and to be incurred by the United States in response to releases or threatened releases of hazardous substances at or from the Site.

The settlement, based on Settling Defendant's limited "ability to pay," requires Settling Defendant to undertake the operation and maintenance of the erosion control structures at the Site; pay the State of Vermont \$5,000 per year for ten years; and stipulate to a judgment in favor of the United States in the amount of \$3,360,082 for EPA's past cleanup costs and in favor of the State in the amount of \$174,620 for the State's past cleanup costs. The Settling Defendant also stipulates to the entry of a judgment in favor of the State for State Future Response Costs estimated to be at least \$28,458,399. These stipulated amounts are to be satisfied only through the recovery of insurance proceeds.

The publication of this notice opens a period for public comment on the Consent Decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to *United States v. Vermont Asbestos Group, Inc.* (D. Vt.) D.J Ref. No. 90-11-3-07425/3. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail:

<i>To submit comments:</i>	<i>Send them to:</i>
By email	<i>pubcomment-ees.enrd@usdoj.gov</i>
By mail	Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044-7611.

During the public comment period, the Consent Decree may be examined and downloaded at this Justice Department Web site: http://www.usdoj.gov/enrd/Consent_

Decrees.html. We will provide paper copies of the consent decree upon written request and payment of reproduction costs. Please mail your request and payment to: Consent Decree Library, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044-7611.

Please enclose a check or money order for \$10.25 (25 cents per page reproduction cost) payable to the United States Treasury.

Robert E. Maher, Jr.,

Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 2013-21856 Filed 9-6-13; 8:45 am]

BILLING CODE 4410-15-P

DEPARTMENT OF JUSTICE

Notice of Lodging of Proposed Consent Decree Under the Comprehensive Environmental Response, Compensation, and Liability Act

On August 29, 2013, the Department of Justice lodged a proposed Consent Decree with the United States District Court for the District of Colorado in the lawsuit entitled *United States v The Dow Chemical Company*, 1:13-cv-2330.

The Consent Decree resolves the claims of the United States set forth in the complaint against The Dow Chemical Company for costs incurred and to be incurred in connection with the Twins Inn Superfund Site ("Site"), located in Arvada, Jefferson County, Colorado, pursuant to Section 107 of the Comprehensive Environmental Response, Compensation, and Liability Act ("CERCLA"), 42 U.S.C. 9607. Under the Consent Decree, the settling defendant agrees to finance and perform the work for the Site and to reimburse \$400,000 in past costs to the United States Environmental Protection Agency.

The publication of this notice opens a period for public comment on the Consent Decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to *United States v. The Dow Chemical Company*, D.J. Ref. No. 90-11-2-08744/1. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail:

<i>To submit comments:</i>	<i>Send them to:</i>
By email	<i>pubcomment-ees.enrd@usdoj.gov</i>

<i>To submit comments:</i>	<i>Send them to:</i>
By mail	Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044–7611.

Under Section 7003(d) of the Resource Conservation and Recovery Act (“RCRA”), a commenter may request an opportunity for a public meeting in the affected area.

During the public comment period, the Consent Decree may be examined and downloaded at this Justice Department Web site: http://www.usdoj.gov/enrd/Consent_Decrees.html. We will provide a paper copy of the Consent Decree upon written request and payment of reproduction costs. Please mail your request and payment to: Consent Decree Library, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044–7611.

Please enclose a check or money order for \$22.25 (25 cents per page reproduction cost) payable to the United States Treasury. For a paper copy without the appendices and signature pages, the cost is \$16.00.

Maureen M. Katz,

Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 2013–21850 Filed 9–6–13; 8:45 am]

BILLING CODE 4410–15–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–378]

Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Established Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2014

AGENCY: Drug Enforcement Administration (DEA), Department of Justice.

ACTION: Notice.

SUMMARY: This notice establishes the initial 2014 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act (CSA) and assessment of annual needs for the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.

DATES: *Effective:* September 9, 2013.

FOR FURTHER INFORMATION CONTACT: Ruth A. Carter, Chief, Policy Evaluation and Analysis Section, Office of

Diversion Control, Drug Enforcement Administration, 8701 Morrisette Drive, Springfield, VA 22152, Telephone: (202) 598–6812.

SUPPLEMENTARY INFORMATION:

Background

Section 306 of the CSA (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II and for the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. This responsibility has been delegated to the Administrator of the DEA by 28 CFR 0.100. The Administrator, in turn, has re-delegated this function to the Deputy Administrator, pursuant to 28 CFR 0.104.

The 2014 aggregate production quotas and assessment of annual needs represent those quantities of Schedules I and II controlled substances and the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine to be manufactured in the United States in 2014 to provide for the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and the establishment and maintenance of reserve stocks. These quotas include imports of ephedrine, pseudoephedrine, and phenylpropanolamine but do not include imports of controlled substances for use in industrial processes.

On July 3, 2013, a notice titled, “Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Proposed Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2014,” was published in the **Federal Register** (78 FR 40186). That notice proposed the 2014 aggregate production quotas for each basic class of controlled substance listed in Schedules I and II and the 2014 assessment of annual needs for the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. All interested persons were invited to comment on or object to the proposed aggregate production quotas and the proposed assessment of annual needs on or before August 2, 2013.

Comments Received

DEA received seven comments from DEA-registered manufacturers within the published comment period on a total of 23 Schedule I and II controlled substances and one List I chemical. Commenters stated that the proposed

aggregate production quotas for (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144), [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11), N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48), cathinone, amphetamine (for sale), codeine (for conversion), codeine (for sale), fentanyl, hydrocodone (for sale), hydromorphone, levomethorphan, methylphenidate, morphine (for conversion), morphine (for sale), noroxymorphone (for conversion), oripavine, oxycodone (for sale), oxymorphone (for conversion), oxymorphone (for sale), phenylacetone, tapentadol, tetrahydrocannabinol, and thebaine were insufficient to provide for the estimated medical, scientific, research, and industrial needs of the United States, export requirements, and the establishment and maintenance of reserve stocks. One commenter stated that the proposed assessment of annual needs quota for phenylpropanolamine (for conversion) was insufficient to provide for the estimated medical, scientific, research, and industrial needs of the United States, export requirements, and the establishment and maintenance of reserve stocks.

Determination of 2014 Aggregate Production Quotas and Assessment of Annual Needs

In determining the 2014 aggregate production quotas and assessment of annual needs, the DEA has taken into consideration the above comments along with the factors set forth at 21 CFR 1303.11 and 21 CFR 1315.11, in accordance with 21 U.S.C. 826(a), and other relevant factors, including the consideration of 2013 manufacturing quotas, current 2013 sales and inventories, 2014 export requirements, industrial use, additional applications for quotas, as well as information on research and product development requirements. Based on this information, the DEA has determined that adjustments to the proposed aggregate production quotas and assessment of annual needs for 1-[1-(2-Thienyl)cyclohexyl]piperidine, carfentanil, cathinone, dihydromorphone, dimethyltryptamine, ecgonine, hydromorphone, levomethorphan, lysergic acid diethylamide, metazocine, methamphetamine, d-methamphetamine (for conversion), methyl-desorphan, noroxymorphone (for conversion), oxymorphone (for conversion), phencyclidine, phenylacetone, ephedrine (for conversion), ephedrine (for sale),